CVS credits private labels
This article was originally published in The Tan Sheet
Executive SummaryCVS Caremark says private label sales are its key growth drivers as consumers continue to cut their spending in the slumping U.S. economy. In a Feb. 19 earnings call, CEO Tom Ryan said CVS' consumer business was "impacted by the recession, but we're somewhat resistant." He said sales of tooth-whitening and salon hair-care products slowed in the firm's fiscal 2008 fourth quarter, but private-label product sales were up. "Our general merchandise is up - consumables, healthcare, beauty," he added. CVS earned $949.3 million in the quarter, a 17 percent increase from $811.2 million a year ago. Fourth-quarter sales at retail drugstore open more than one year increased 18.8 percent to $13.8 billion, the firm says. The Woonsocket, R.I.-based chain's net revenue for the October-December period increased 10 percent to $24.1 billion. The firm says its total revenue for the year increased 14.6 percent to $87.5 billion
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.